KLP Kapitalforvaltning AS Acquires New Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

KLP Kapitalforvaltning AS bought a new stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 8,000 shares of the company’s stock, valued at approximately $158,000.

Several other large investors have also recently bought and sold shares of the stock. Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $50,000. China Universal Asset Management Co. Ltd. boosted its holdings in Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after buying an additional 1,004 shares in the last quarter. Teacher Retirement System of Texas grew its position in Kiniksa Pharmaceuticals by 7.1% in the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock worth $215,000 after buying an additional 719 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at $258,000. Finally, New York State Common Retirement Fund increased its holdings in shares of Kiniksa Pharmaceuticals by 12.4% in the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock valued at $302,000 after buying an additional 1,680 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Insiders Place Their Bets

In related news, COO Eben Tessari sold 14,000 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $18.24, for a total transaction of $255,360.00. Following the completion of the sale, the chief operating officer now owns 88,975 shares in the company, valued at $1,622,904. This represents a 13.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Mark Ragosa sold 8,879 shares of the firm’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total transaction of $205,104.90. Following the completion of the sale, the chief financial officer now owns 23,382 shares in the company, valued at approximately $540,124.20. The trade was a 27.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 93,766 shares of company stock valued at $2,011,735 over the last ninety days. Corporate insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Trading Down 3.9 %

Shares of Kiniksa Pharmaceuticals stock opened at $19.48 on Wednesday. The company has a market cap of $1.42 billion, a P/E ratio of -139.13 and a beta of 0.31. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $16.56 and a 1 year high of $28.15. The stock has a 50-day moving average price of $20.96 and a 200 day moving average price of $21.74.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $122.50 million for the quarter, compared to analysts’ expectations of $123.42 million. During the same period in the previous year, the firm posted $0.35 earnings per share. The business’s revenue for the quarter was up 46.9% on a year-over-year basis. On average, equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KNSA. Citigroup started coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $37.17.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.